Amgen Inc (AMGN)
262.75
-1.32
(-0.50%)
USD |
NASDAQ |
Apr 18, 16:00
262.52
-0.23
(-0.09%)
After-Hours: 05:19
Amgen Research and Development Expense (TTM): 4.784B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.784B |
| September 30, 2023 | 4.574B |
| June 30, 2023 | 4.607B |
| March 31, 2023 | 4.533B |
| December 31, 2022 | 4.434B |
| September 30, 2022 | 4.458B |
| June 30, 2022 | 4.768B |
| March 31, 2022 | 4.811B |
| December 31, 2021 | 4.819B |
| September 30, 2021 | 4.70B |
| June 30, 2021 | 4.34B |
| March 31, 2021 | 4.222B |
| December 31, 2020 | 4.207B |
| September 30, 2020 | 4.29B |
| June 30, 2020 | 4.229B |
| March 31, 2020 | 4.189B |
| December 31, 2019 | 4.116B |
| September 30, 2019 | 3.986B |
| June 30, 2019 | 3.911B |
| March 31, 2019 | 3.856B |
| December 31, 2018 | 3.737B |
| September 30, 2018 | 3.598B |
| June 30, 2018 | 3.549B |
| March 31, 2018 | 3.553B |
| December 31, 2017 | 3.562B |
| Date | Value |
|---|---|
| September 30, 2017 | 3.597B |
| June 30, 2017 | 3.71B |
| March 31, 2017 | 3.737B |
| December 31, 2016 | 3.84B |
| September 30, 2016 | 3.855B |
| June 30, 2016 | 3.984B |
| March 31, 2016 | 4.048B |
| December 31, 2015 | 4.07B |
| September 30, 2015 | 4.211B |
| June 30, 2015 | 4.11B |
| March 31, 2015 | 4.164B |
| December 31, 2014 | 4.297B |
| September 30, 2014 | 4.312B |
| June 30, 2014 | 4.283B |
| March 31, 2014 | 4.232B |
| December 31, 2013 | 4.083B |
| September 30, 2013 | 3.772B |
| June 30, 2013 | 3.663B |
| March 31, 2013 | 3.522B |
| December 31, 2012 | 3.38B |
| September 30, 2012 | 3.293B |
| June 30, 2012 | 3.174B |
| March 31, 2012 | 3.167B |
| December 31, 2011 | 3.167B |
| September 30, 2011 | 3.17B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.911B
Minimum
Jun 2019
4.819B
Maximum
Dec 2021
4.420B
Average
4.434B
Median
Dec 2022
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences Inc | 5.719B |
| Johnson & Johnson | 15.30B |
| Eli Lilly and Co | 9.313B |
| Merck & Co Inc | 30.53B |
| Vertex Pharmaceuticals Inc | 3.163B |